Thousands of men to benefit from new prostate cancer drug approved for use on NHS
Related news coverage
Noxopharm Ltd (ASX:NOX) chief executive officer and managing director Dr Graham Kelly has highlighted the company’s achievements..
Noxopharm set to benefit from new data showing experimental drug Lu-PSMA-617 to become important treatment for late-stage prostate cancer
Noxopharm Ltd (ASX:NOX) welcomes news that Novartis' experimental drug, 177Lutetium-PSMA-617 (Lu-PSMA-617), looks set to become..